BOGOTA, Colombia – An administrative decision in Brazil canceled the patent for bevacizumab following a lawsuit filed by domestic generics manufacturers. The Brazilian Association of Industries of Generics (ProGenéricos in Portuguese), which represents the companies that distribute around 90 percent of the generics sold in Brazil, took on the patent at the source.